Anti-MUSK myasthenia gravis (MG): treatment
Evidence-based neurology checklist on anti-musk myasthenia gravis (mg): treatment: Beneficial treatments Rituximab 3,4 diaminopyridine Rozanolixizumab Investigational treatments Treatments for severe exacerbations Non-beneficial treatments: anti-acetylcholinesterase inhibitors Non-beneficial…
Beneficial treatments
- Rituximab
- 3,4 diaminopyridine
- Rozanolixizumab
Investigational treatments
Treatments for severe exacerbations
Non-beneficial treatments: anti-acetylcholinesterase inhibitors
Non-beneficial treatments: thymectomy
Potential markers of clinical improvement
References
- Wolfe GI, Oh SJ. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann N Y Acad Sci 2008; 1132:71-75.
- Takahashi H, Kawaguchi N, Ito N, Takamichi H, Kuwabara S. Is tongue atrophy reversible in anti-MUSK myasthenia gravis? Six year observation. JNNP 2010; 81:701-702.
- Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014; 175:408-418.
- Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology 2017; 89:1069-1077.
- Cortés-Vicente E, Rojas-Garcia R, Díaz-Manera J, et al. The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin Transl Neurol 2018; 5:710-716.
- And 5 more. Subscribe to see the full list
